Clinical Trial Update: Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating nintedanib with capecitabine in refractory metastatic colorectal cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Adenocarcinoma
• Colon Carcinoma
• Rectal Adenocarcinoma
• Rectal Carcinoma
• Stage Iva Colon Cancer
• Stage Iva Rectal Cancer
• Stage Ivb Colon Cancer
• Stage Ivb Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Nintedanib (nintedanib)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-07-07